Adaptive Biotechnologies (ADPT) Cash from Investing Activities (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Cash from Investing Activities data on file, last reported at $9.1 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 64.25% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.5 million (down 63.44% YoY) and the FY2025 annual result came in at $37.9 million, down 51.22% from the prior year.
• Cash from Investing Activities climbed to $9.1 million in Q1 2026 per ADPT's latest filing, from -$8.3 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $63.0 million in Q1 2023, with the low at -$97.5 million in Q4 2022.
• Average Cash from Investing Activities over 5 years is $15.1 million, with a median of $17.3 million recorded in 2025.
• Year-over-year, Cash from Investing Activities tumbled 245.13% in 2022 and surged 686.41% in 2023.
• Adaptive Biotechnologies' Cash from Investing Activities stood at -$97.5 million in 2022, then jumped by 103.29% to $3.2 million in 2023, then soared by 589.71% to $22.1 million in 2024, then tumbled by 137.31% to -$8.3 million in 2025, then soared by 210.8% to $9.1 million in 2026.
• Business Quant data shows ADPT's Cash from Investing Activities at $9.1 million in Q1 2026, -$8.3 million in Q4 2025, and $17.3 million in Q3 2025.